Evidence map›Paper›PMID 41378298›Full record

ArticleFrontiers in oncology2025

Correlation analysis between EGFR gene mutation status, ALK positivity and demographic data, tumor biomarkers, radiological and pathological features in patients with lung adenocarcinoma.

Xue Fei Zhang, Xu Zhang, Liang Zhao, Zhi Long Zhao

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xue Fei ZhangDepartment of Thoracic Surgery, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China.
Xu ZhangDepartment of Thoracic Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
Liang ZhaoSchool of Software Technology, Dalian University of Technology, Dalian, Liaoning, China.
Zhi Long ZhaoDepartment of Thoracic Surgery, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to explore the relationship between EGFR mutations, ALK positivity, and demographic, tumor, radiological, and pathological characteristics in lung adenocarcinoma patients. Methods: This study included 626 patients with early-stage lung adenocarcinoma who underwent surgical resection between October 2017 and December 2023.EGFR and ALK mutations were analyzed postoperatively. Clinical, pathological, and imaging features such as gender, age, smoking status, and tumor characteristics were assessed. Patients were categorized based on their mutation status, and comparisons were made regarding their clinical and imaging features. Results: Results indicated that EGFR-positive patients were predominantly female, younger, and had a higher frequency of non-smokers compared to the wild-type (WT) group. EGFR mutations, particularly the exon 19 deletions and L858R mutations, were more common in patients with moderate differentiation and lepidic or acinar predominant histological subtypes. CT imaging revealed that EGFR-positive tumors were smaller in size and had fewer solid components compared to WT tumors. Additionally, certain CT features such as the spicule sign and air bronchogram were significantly associated with EGFR mutations. For ALK mutations, the analysis showed that patients with ALK-positive tumors had distinct radiological features, including a higher occurrence in the lower lobes and fewer ground glass nodules compared to the WT group. Conclusions: The study concluded that specific radiological and pathological characteristics, along with EGFR and ALK mutation statuses, could be used to guide the treatment and diagnosis of lung adenocarcinoma.

Indexed as

ALK positivitydemographic dataEGFR gene mutationimaginglung adenocarcinomaspathologytumor biomarkers

Identifiers

PMID41378298
PMCPMC12685631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.